Used for: ROS1-positive non-small cell lung cancer · Solid tumors with an NTRK gene fusion · 1 more
How to pay the least
Ask for the cash price
Rozlytrek
We didn’t find one.
What to do
Ask your pharmacy for Rozlytrek’s cash price, and one or two other pharmacies too.
Other ways
Free from the maker, if you qualify Genentech Patient Foundation. Do not have insurance coverage for their Genentech medicine and their household makes less than $150,000 per year Or call (888) 941-3331.
ROZLYTREK is a kinase inhibitor indicated for the treatment of:
Adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Adult and pediatric patients older than 1 month of age with solid tumors that:
have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation,
are metastatic or where surgical resection is likely to result in severe morbidity, and
have progressed following treatment or have no satisfactory alternative therapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Source: the FDA label for Rozlytrek (Genentech, Inc.), October 8, 2026. Full label on DailyMed
Good to know
“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Check the maker’s page for who can use it.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/rozlytrek/